Does the media prefer LUCD or ALLO?

In the previous week, Lucid Diagnostics and Lucid Diagnostics both had 2 articles in the media. Lucid Diagnostics' average media sentiment score of 1.13 beat Allogene Therapeutics' score of 0.97 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARVN or LUCD more profitable?

Arvinas has a net margin of 2.94% compared to Lucid Diagnostics' net margin of -959.76%. Arvinas' return on equity of 1.91% beat Lucid Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Arvinas 2.94% 1.91% 1.29% Lucid Diagnostics -959.76% N/A -119.57%

Does the media refer more to ARVN or LUCD?

In the previous week, Arvinas had 6 more articles in the media than Lucid Diagnostics. MarketBeat recorded 8 mentions for Arvinas and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.13 beat Arvinas' score of 0.43 indicating that Lucid Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MPLT or LUCD?

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 2 articles in the media. Lucid Diagnostics' average media sentiment score of 1.13 beat Maplight Therapeutics' score of 0.70 indicating that Lucid Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EPRX or LUCD?

In the previous week, Eupraxia Pharmaceuticals had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Eupraxia Pharmaceuticals and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.13 beat Eupraxia Pharmaceuticals' score of 0.91 indicating that Lucid Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RZLT or LUCD?

In the previous week, Rezolute had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for Rezolute and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.13 beat Rezolute's score of 0.47 indicating that Lucid Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lucid Diagnostics (LUCD) Competitors

$0.55 -0.06 (-9.08%)

As of 02:30 PM Eastern

Compare

LUCD vs. ALLO, ARVN, MPLT, EPRX, and RZLT

Should you buy Lucid Diagnostics stock or one of its competitors? Lucid Diagnostics's main competitors and comparable companies include Allogene Therapeutics (ALLO), Arvinas (ARVN), Maplight Therapeutics (MPLT), Eupraxia Pharmaceuticals (EPRX), and Rezolute (RZLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lucid Diagnostics compare to Allogene Therapeutics?

Lucid Diagnostics (NASDAQ:LUCD) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Lucid Diagnostics presently has a consensus price target of $4.19, indicating a potential upside of 591.01%. Allogene Therapeutics has a consensus price target of $8.30, indicating a potential upside of 543.41%. Given Lucid Diagnostics' higher possible upside, research analysts plainly believe Lucid Diagnostics is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

In the previous week, Lucid Diagnostics and Lucid Diagnostics both had 2 articles in the media. Lucid Diagnostics' average media sentiment score of 1.13 beat Allogene Therapeutics' score of 0.97 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lucid Diagnostics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	26.15	-$58.01M	-$0.47	N/A
Allogene Therapeutics	$20K	22,284.11	-$190.89M	-$0.67	N/A

Allogene Therapeutics has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Lucid Diagnostics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Allogene Therapeutics beats Lucid Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Lucid Diagnostics compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Lucid Diagnostics has lower revenue, but higher earnings than Arvinas. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	1.68	-$80.80M	$0.10	68.40
Lucid Diagnostics	$4.71M	26.15	-$58.01M	-$0.47	N/A

Arvinas presently has a consensus price target of $14.55, indicating a potential upside of 112.65%. Lucid Diagnostics has a consensus price target of $4.19, indicating a potential upside of 591.01%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.50
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Arvinas has a net margin of 2.94% compared to Lucid Diagnostics' net margin of -959.76%. Arvinas' return on equity of 1.91% beat Lucid Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
Lucid Diagnostics	-959.76%	N/A	-119.57%

In the previous week, Arvinas had 6 more articles in the media than Lucid Diagnostics. MarketBeat recorded 8 mentions for Arvinas and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.13 beat Arvinas' score of 0.43 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arvinas has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Summary

Arvinas beats Lucid Diagnostics on 11 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 2 articles in the media. Lucid Diagnostics' average media sentiment score of 1.13 beat Maplight Therapeutics' score of 0.70 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

74.0% of Lucid Diagnostics shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Maplight Therapeutics has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
Lucid Diagnostics	-959.76%	N/A	-119.57%

Lucid Diagnostics has higher revenue and earnings than Maplight Therapeutics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
Lucid Diagnostics	$4.71M	26.15	-$58.01M	-$0.47	N/A

Maplight Therapeutics currently has a consensus price target of $29.50, suggesting a potential upside of 274.37%. Lucid Diagnostics has a consensus price target of $4.19, suggesting a potential upside of 591.01%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.89
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Lucid Diagnostics beats Maplight Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Lucid Diagnostics compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Eupraxia Pharmaceuticals had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Eupraxia Pharmaceuticals and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.13 beat Eupraxia Pharmaceuticals' score of 0.91 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals presently has a consensus price target of $17.80, indicating a potential upside of 166.47%. Lucid Diagnostics has a consensus price target of $4.19, indicating a potential upside of 591.01%. Given Lucid Diagnostics' higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Eupraxia Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Lucid Diagnostics	-959.76%	N/A	-119.57%

74.0% of Lucid Diagnostics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Lucid Diagnostics. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Lucid Diagnostics	$4.71M	26.15	-$58.01M	-$0.47	N/A

Summary

Lucid Diagnostics beats Eupraxia Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Lucid Diagnostics compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Rezolute presently has a consensus target price of $11.22, indicating a potential upside of 143.43%. Lucid Diagnostics has a consensus target price of $4.19, indicating a potential upside of 591.01%. Given Lucid Diagnostics' higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Rezolute had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for Rezolute and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.13 beat Rezolute's score of 0.47 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 14.8% of Rezolute shares are owned by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Rezolute has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-62.99%	-57.94%
Lucid Diagnostics	-959.76%	N/A	-119.57%

Rezolute has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Lucid Diagnostics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A
Lucid Diagnostics	$4.71M	26.15	-$58.01M	-$0.47	N/A

Summary

Rezolute and Lucid Diagnostics tied by winning 7 of the 14 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUCD vs. The Competition

Export

Metric	Lucid Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$112.80M	$3.91B	$7.28B	$12.93B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-1.17	12.99	275.40	25.27
Price / Sales	23.78	1,152.92	562.90	78.90
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-1.78	16.61	10.55	5.93
Net Income	-$58.01M	-$22.69M	$3.50B	$380.91M
7 Day Performance	-11.63%	-6.02%	-3.94%	-4.21%
1 Month Performance	-29.59%	-13.82%	-8.33%	-7.05%
1 Year Performance	-53.70%	6.88%	2.44%	-4.87%

Lucid Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUCD Lucid Diagnostics	2.2059 of 5 stars	$0.55 -9.1%	$4.19 +660.0%	-48.6%	$112.80M	$4.71M	N/A	82	Positive News Gap Down
ALLO Allogene Therapeutics	3.7097 of 5 stars	$1.29 -7.9%	$8.30 +543.4%	+1.6%	$483.69M	$20K	N/A	152	Positive News
ARVN Arvinas	3.2853 of 5 stars	$6.84 -8.2%	$14.55 +112.7%	-30.2%	$480.68M	$262.60M	68.41	246
MPLT Maplight Therapeutics	3.5721 of 5 stars	$7.88 -8.4%	$29.50 +274.4%	N/A	$477.95M	N/A	N/A	133	News Coverage Positive News
EPRX Eupraxia Pharmaceuticals	3.0198 of 5 stars	$6.68 -8.7%	$17.80 +166.5%	+10.4%	$475.94M	N/A	N/A	49

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUCD) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lucid Diagnostics (LUCD) Competitors

LUCD vs. ALLO, ARVN, MPLT, EPRX, and RZLT

How does Lucid Diagnostics compare to Allogene Therapeutics?

Summary

How does Lucid Diagnostics compare to Arvinas?

Summary

How does Lucid Diagnostics compare to Maplight Therapeutics?

Summary

How does Lucid Diagnostics compare to Eupraxia Pharmaceuticals?

Summary

How does Lucid Diagnostics compare to Rezolute?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lucid Diagnostics (LUCD) Competitors

LUCD vs. ALLO, ARVN, MPLT, EPRX, and RZLT

How does Lucid Diagnostics compare to Allogene Therapeutics?

Do analysts rate LUCD or ALLO?

Does the media prefer LUCD or ALLO?

Which has higher valuation and earnings, LUCD or ALLO?

Is LUCD or ALLO more profitable?

Which has more volatility and risk, LUCD or ALLO?

Do insiders & institutionals have more ownership in LUCD or ALLO?

Summary

How does Lucid Diagnostics compare to Arvinas?

Which has better valuation & earnings, ARVN or LUCD?

Do analysts rate ARVN or LUCD?

Is ARVN or LUCD more profitable?

Does the media refer more to ARVN or LUCD?

Do insiders and institutionals believe in ARVN or LUCD?

Which has more risk and volatility, ARVN or LUCD?

Summary

How does Lucid Diagnostics compare to Maplight Therapeutics?

Does the media favor MPLT or LUCD?

Do insiders and institutionals have more ownership in MPLT or LUCD?

Is MPLT or LUCD more profitable?

Which has better earnings & valuation, MPLT or LUCD?

Do analysts prefer MPLT or LUCD?

Summary

How does Lucid Diagnostics compare to Eupraxia Pharmaceuticals?

Does the media refer more to EPRX or LUCD?

Do analysts rate EPRX or LUCD?

Which has more volatility & risk, EPRX or LUCD?

Is EPRX or LUCD more profitable?

Do insiders & institutionals believe in EPRX or LUCD?

Which has better earnings and valuation, EPRX or LUCD?

Summary

How does Lucid Diagnostics compare to Rezolute?

Do analysts recommend RZLT or LUCD?

Does the media favor RZLT or LUCD?

Do insiders and institutionals believe in RZLT or LUCD?

Is RZLT or LUCD more profitable?

Which has more risk & volatility, RZLT or LUCD?

Which has better valuation & earnings, RZLT or LUCD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools